New and emerging medical therapies in Parkinson’s disease

Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial

(2015) C. Warren Olanow et al.   ANNALS OF NEUROLOGY

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

(2015) Per Svenningsson et al.   BRAIN

A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease

(2015) Tomoyoshi Kondo et al.   CLINICAL NEUROPHARMACOLOGY

Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial

(2015) Cheryl H. Waters et al.   CNS DRUGS

Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease

(2015) J. J. Ferreira et al.   EUROPEAN JOURNAL OF NEUROLOGY

Apomorphine hydrochloride for the treatment of Parkinson’s disease

(2015) Elisa Unti et al.   Expert Review of Neurotherapeutics

Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease

(2015) Karl Kieburtz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Epigenetic mechanisms in Parkinson's disease

(2015) Ya Feng et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Transcutaneous Tibial Nerve Stimulation in the Treatment of Lower Urinary Tract Symptoms and Its Impact on Health-Related Quality of Life in Patients With Parkinson Disease

(2015) Maria Carolina Perissinotto et al.   Journal of Wound Ostomy and Continence Nursing

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations

(2015) Benjamin Dehay et al.   LANCET NEUROLOGY

Gastrointestinal dysfunction in Parkinson's disease

(2015) Alfonso Fasano et al.   LANCET NEUROLOGY

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015)   LANCET NEUROLOGY

Advances in functional neurosurgery for Parkinson's disease

(2015) Leo Verhagen Metman et al.   MOVEMENT DISORDERS

Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study

(2015) Miho Murata et al.   MOVEMENT DISORDERS

New treatments for levodopa-induced motor complications

(2015) Olivier Rascol et al.   MOVEMENT DISORDERS

Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease

(2015) Leo Verhagen Metman et al.   MOVEMENT DISORDERS

Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)

(2015) Rajesh Pahwa et al.   MOVEMENT DISORDERS

Cell-based therapies for Parkinson disease—past insights and future potential

(2015) Roger A. Barker et al.   Nature Reviews Neurology

Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease

(2015) D. Calandrella et al.   NEUROLOGY

Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry

(2015) Maríateresa Buongiorno et al.   PARKINSONISM & RELATED DISORDERS

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

(2015) Theresa A. Zesiewicz et al.   PARKINSONISM & RELATED DISORDERS

Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease

(2015) Chun-Hyung Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apomorphine hydrochloride for the treatment of Parkinson’s disease

(2015) Elisa Unti et al.   Expert Review of Neurotherapeutics

A Nurr1 Agonist Causes Neuroprotection in a Parkinson’s Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C)

(2015) Gaynor A. Smith et al.   PLoS One

Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

(2014) Annalisa Pinna   CNS DRUGS

Therapeutic potential of targeting glutamate receptors in Parkinson’s disease

(2014) Clare Finlay et al.   JOURNAL OF NEURAL TRANSMISSION

Adenosine 2A Receptor Occupancy by Tozadenant and Preladenant in Rhesus Monkeys

(2014) O. Barret et al.   JOURNAL OF NUCLEAR MEDICINE

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

(2014) Robert A Hauser et al.   LANCET NEUROLOGY

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

(2014) Erwan Bezard et al.   MOVEMENT DISORDERS

Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease

(2014) Rupam Borgohain et al.   MOVEMENT DISORDERS

Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)

(2014) Robert A. Hauser et al.   MOVEMENT DISORDERS

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results

(2014) Hubert H. Fernandez et al.   MOVEMENT DISORDERS

Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

(2014) Peter A. LeWitt   MOVEMENT DISORDERS

Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson’s disease: a meta-analysis

(2014) Chuan Zhu et al.   NEUROLOGICAL RESEARCH

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial

(2014) H. Kaufmann et al.   NEUROLOGY

Deep-Brain Stimulation — Entering the Era of Human Neural-Network Modulation

(2014) Michael S. Okun   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of IPX066 with carbidopa–levodopa plus entacapone in advanced PD patients

(2014) Fabrizio Stocchi et al.   PARKINSONISM & RELATED DISORDERS

Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease

(2014) Christopher Kobylecki et al.   PARKINSONISM & RELATED DISORDERS

Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease

(2014) Michael A. Schwarzschild et al.   JAMA Neurology

Parkinson Disease Subtypes

(2014) Mary Ann Thenganatt et al.   JAMA Neurology

A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

(2014) et al.   JAMA Neurology

Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates

(2014) Nicolas Morin et al.   Frontiers in Neurology

Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil

(2013) Stéphane Thobois et al.   BRAIN

Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial

(2013) D. Devos et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

(2013) Jeffrey Cummings et al.   LANCET

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial

(2013) Robert A Hauser et al.   LANCET NEUROLOGY

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

(2013) Anthony HV Schapira et al.   LANCET NEUROLOGY

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study

(2013) C Warren Olanow et al.   LANCET NEUROLOGY

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease

(2013) Peter A. LeWitt et al.   MOVEMENT DISORDERS

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

(2013) Rupam Borgohain et al.   MOVEMENT DISORDERS

Adenosine A2Areceptor antagonist istradefylline reduces daily OFF time in Parkinson's disease

(2013) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

(2013) Fabrizio Stocchi et al.   MOVEMENT DISORDERS

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)

(2013)   MOVEMENT DISORDERS

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia

(2013) Erwan Bezard et al.   MOVEMENT DISORDERS

Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease

(2013) Amaal AlDakheel et al.   Neurotherapeutics

Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease

(2013) Rajesh Pahwa et al.   PARKINSONISM & RELATED DISORDERS

Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP): Table 1

(2013) Hideyuki Sawada et al.   BMJ Open

Pharmacokinetics of Levodopa/Carbidopa Microtablets Versus Levodopa/Benserazide and Levodopa/Carbidopa in Healthy Volunteers

(2012) Dag Nyholm et al.   CLINICAL NEUROPHARMACOLOGY

Actively Transported Levodopa Prodrug XP21279

(2012) Peter A. LeWitt et al.   CLINICAL NEUROPHARMACOLOGY

Pharmacokinetics and Pharmacodynamics of Gastroretentive Delivery of Levodopa/Carbidopa in Patients With Parkinson Disease

(2012) Cuiping Chen et al.   CLINICAL NEUROPHARMACOLOGY

Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease

(2012) M. A. Cenci et al.   CNS & Neurological Disorders-Drug Targets

Emerging therapies for Parkinsonʼs disease

(2012) Werner Poewe et al.   CURRENT OPINION IN NEUROLOGY

Therapies in Parkinsonʼs disease

(2012) Joseph Jankovic et al.   CURRENT OPINION IN NEUROLOGY

Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study

(2012) Maurizio Zibetti et al.   JOURNAL OF NEUROLOGY

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients

(2012) Jay S. Schneider et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study)

(2012) P. A. LeWitt et al.   NEUROLOGY

 -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons

(2012) M. Decressac et al.   Science Translational Medicine

Preclinical Biomarkers of Parkinson Disease

(2011) Yuncheng Wu et al.   ARCHIVES OF NEUROLOGY

A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients

(2011) Santiago Perez Lloret et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

(2011) Daniela Berg et al.   MOVEMENT DISORDERS

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

(2011) Susan H. Fox et al.   MOVEMENT DISORDERS

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

(2011) A. F. Ramlackhansingh et al.   NEUROLOGY

Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study

(2011) Emmanuelle Pourcher et al.   PARKINSONISM & RELATED DISORDERS

Efficacy of zonisamide in a case of Parkinson’s disease with intractable resting and re-emergent tremor

(2010) M. Iijima et al.   EUROPEAN JOURNAL OF NEUROLOGY

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease

(2010) K. J. Black et al.   JOURNAL OF NEUROSCIENCE

Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease

(2010) T. H. Johnston et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Abstracts of The Movement Disorder Society's Thirteenth International Congress of Parkinson's Disease and Movement Disorders

(2010)   MOVEMENT DISORDERS

The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates

(2010) Tom H. Johnston et al.   MOVEMENT DISORDERS

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys

(2010) Daniella Rylander et al.   NEUROBIOLOGY OF DISEASE

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease

(2009) Alberto Ascherio   ARCHIVES OF NEUROLOGY

A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death

(2009) Kaoru Saijo et al.   CELL

Development of swelling/floating gastroretentive drug delivery system based on a combination of hydroxyethyl cellulose and sodium carboxymethyl cellulose for Losartan and its clinical relevance in healthy volunteers with CYP2C9 polymorphism

(2009) Ray-Neng Chen et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

(2009) Bazoumana Ouattara et al.   NEUROBIOLOGY OF AGING

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

(2008) Robert A. Hauser et al.   MOVEMENT DISORDERS

Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study

(2008) Pedro J. García Ruiz et al.   MOVEMENT DISORDERS

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

(2008) M. Stacy et al.   NEUROLOGY